Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.15 (
renin
)
35,795
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of thyroid hormone on
renin
productiona and release by rat kidney slices was studied. Rat kidney slices were incubated in Warburg flasks containing Krebs-Ringer-Phosphate- Glucose- Dextran solution at 37 C for 5 hours. Renin content,
renin
released into the incubation media and oxygen consumption were measured. Kidney slices actively secreted
renin
. Kidney slices of hyperthyroid rats released more
renin
, and kidney slices of hypothyroid rats released less
renin
than normal kidneys (p less than 0.001). The addition of 1-thyroxine to the incubation medium increased significantly (p less than 0.001)
renin
release by kidney slices from normal and hypothyroid rats. Thyroid hormone affects
renin
release through a mechanism independent of the ouabain-sensitive
sodium pump
and protein synthesis, since ouabain and cycloheximide did not modify
renin
release or production. The results of this study suggest that thyroid hormone plays a role in
renin
release from the juxtaglomerular cells.
...
PMID:The effect of thyroid hormone on renin production and release by rat kidney slices. 61 72
To evaluate the importance of an endogenous
sodium pump
inhibitor in the pathogenesis of low
renin
human hypertension, the urinary excretion of a digoxin-like immunoreactive substance (DLIS) was measured in eight patients with primary aldosteronism (n = 5, with adenomas) during two sequential 1-week periods of low- (20 mmol/l NaCl) and high- (200 mmol/l NaCl) sodium intake. DLIS excretion increased consistently during high-sodium intake while urinary aldosterone, plasma
renin
activity, cortisol and adrenocorticotropic hormone did not change. Although blood pressure showed a time-course parallel to that of the urinary DLIS, the blood pressure increments were not accompanied by evidence of vasoconstriction since forearm blood flow (plethysmographic technique) increased and forearm vascular resistances were reduced. Moreover, the reactivity of forearm arterioles to local norepinephrine was unchanged during the period of low- and high-salt intake, despite the fact that an endogenous
sodium pump
inhibitor should, supposedly, sensitize the responses to an adrenergic agonist. Finally, forearm vasoconstrictor responses to ouabain, a pharmacological Na+,K(+)-ATPase antagonist, were potentiated during the high-salt diet, a result not expected if an increased number of sodium pumps were occupied by an endogenous inhibitor. These results provide unequivocal evidence for a modulation by salt intake of the urinary excretion of a DLIS in patients with primary aldosteronism. This substance might participate in the regulation of body fluid volume in this syndrome and possibly in other physiological conditions. However, no evidence could be found for a cause--effect relationship between blood pressure and DLIS increments during high-salt intake, at least during the short-term course of the study.
...
PMID:Does a digoxin-like substance participate in vascular and pressure control during dietary sodium changes in patients with primary aldosteronism? 164 66
Natriuretic hormone is a digoxin-like substance that inhibits Na-K-ATPase, membraneous
sodium pump
, leads to storage of sodium in the cells, increases their tone which plays a key role in the increase of peripheral resistance of the blood vessels and progression of hypertensive disease. Results indicate that the level of natriuretic hormone was increased at all stages of hypertensive disease, positively correlated with aldosterone and kallikrein and negatively--with the plasma
renin
activity that confirms its pressor action.
...
PMID:[The role of the natriuretic hormone in neurohumoral regulation in hypertension]. 168 83
Maximum binding of ouabain to erythrocytes (Bmax), serum K, urinary aldosterone excretion (U-Aldo) and fractional excretion of filtered K (FEK) were examined in 69 healthy children aged 12 to 15 years to assess the relationship between the
sodium pump
receptor in erythrocytes and the renal handling of potassium (K). Bmax showed a significant negative correlation with FEK. Subsequently, FEK showed a negative correlation with serum K which was within normal range in every child, and a positive correlation with U-Aldo. However, Bmax showed no correlation with serum K or U-Aldo. These findings suggest that aldosterone may influence Bmax via the changes in FEK and serum K within physiological ranges. In other words, there can exist a close relation between Bmax and the
renin
-angiotensin-aldosterone system through K metabolism.
...
PMID:[A close relationship between the renal potassium regulation and the maximum binding of ouabain to erythrocytes]. 205 38
The present study was conducted in 15 essential hypertensives to evaluate the modifications of plasma levels of an endogenous Na/K ATPase inhibitor, blood pressure, forearm hemodynamics and plasma
renin
activity (PRA) elicited by an intravenous saline infusion (0.9% NaCl at the mean rate of 0.22 mL/min/kg body weight for 2 h). The response to saline was determined in the whole hypertensive population as well as in two subgroups of patients classified according to their rate of PRA suppression in response to volume expansion by comparison with normotensive controls (Normal- and Low-suppressors: N-S, L-S). Over the whole group of hypertensive patients, NaCl load provoked an increase in Na/K ATPase inhibitory activity, measured by enzyme-coupled assay, which was linearly related to PRA decline (r = 0.73) and to the increase in mean blood pressure (r = 0.57). These effects were clearly enhanced by considering L-S patients alone. Urinary Na/K ratio after saline infusion was significantly higher in L-S as result of a lesser potassium excretion in this subgroup. Our results support the hypothesis that acute volume expansion with saline causes an increase in plasma levels of an endogenous
sodium pump
inhibitor with hemodynamic effects and whose release is related to the individual handling of infused fluids and to the degree of
renin
-angiotensin-aldosterone suppression.
...
PMID:Short-term plasma renin activity suppression by saline and release of a plasma endogenous Na/K ATPase inhibitor in essential hypertension. 215 4
There is controversy about the effects of dietary sodium deprivation on cellular cation transport. Using washed erythrocytes for in vitro 22Na and 86Rb uptake studies, we studied the effects of a strict low-salt diet (20 mmol/day) for 4 days in 14 normotensive and 13 hypertensive subjects. Urinary sodium excretion fell from 147 +/- 13 to 18 +/- 3 mmol/24 h in the normotensive group and from 155 +/- 16 to 20 +/- 2 mmol/24 h in the hypertensive group. In both groups, there was a fall in plasma sodium concentration and activation of the
renin
-aldosterone axis. Both systolic and diastolic blood pressures fell in the hypertensive, but not the normotensive group. There were small but significant (P less than 0.025) decreases in cell cation concentrations and passive cation transport in the normotensive, but not the hypertensive group. No significant change in
sodium pump
activity or in Na+K+ cotransport was seen in either group. These observations provide no support for the concept that a decrease in dietary sodium intake can induce changes in cell cation transport, detectable in vitro, to which reduction in blood pressure may be attributed.
...
PMID:Effects of dietary sodium deprivation on erythrocyte sodium concentration and cation transport in normotensive and untreated hypertensive subjects. 242 Aug 63
The possible roles of a humoral
sodium pump
inhibitor and atrial natriuretic peptide in low
renin
hypertension are considered, relying heavily on data from a classical animal model of low
renin
hypertension, the reduced renal mass-saline model in the rat, and on data uncovered by a new literature survey of the two agents in various normotensive and hypertensive states. Based on these data, particularly those indicating both agents are released by volume expansion, our current view is that low
renin
hypertension is in part generated by the
sodium pump
inhibitor and is in part moderated by atrial natriuretic peptide. We suggest that the atrial natriuretic peptide compensates for increased volume due to reduced renal function and/or increased salt intake and that in low
renin
hypertension the compensation is not sufficient to return volume and pressure to normal. In this view, the
sodium pump
inhibitor is prohypertensive, via actions on blood vessels and heart, and atrial natriuretic peptide is antihypertensive, via actions on kidney and the cardiovascular system.
...
PMID:Natriuretic hormones in low renin hypertension. 243 43
Anatagonists to angiotensin, catecholamines, aldosterone, and vasopressin have long been used to help determine agonist roles in hypertension. We here call attention to a possible extension of this approach to detect, evaluate, and treat vascular sodium transport defects in hypertension. Two basic types of transport defects have been identified in the blood vessels of hypertensive animals, increased sodium permeability and decreased
sodium pump
activity. Intravenous injection of 6-iodo-amiloride, a sodium channel blocker and vasodilator, produces an immediate and sustained decrease in blood pressure in two genetic models of hypertension characterized by increased permeability of the vascular smooth muscle cell membrane to sodium (Okamoto spontaneously hypertensive rat, Dahl salt sensitive rat), whereas it produces only a transient fall in arterial pressure in two renal models of hypertension having normal sodium permeability in vascular smooth muscle cells (reduced renal mass-saline rat, one-kidney, one clip rat). Canrenone, a metabolic product of spironolactone which can compete with oubain for binding to Na+,K+-ATPase at the digitalis receptor site, decreases blood pressure in a low
renin
, volume expanded model of hypertension which has been shown to have depressed
sodium pump
activity in arteries and increased
sodium pump
inhibitor in plasma (reduced renal mass-saline rat) but has no effect on blood pressure in a genetic model of hypertension which has been shown to have increased
sodium pump
activity secondary to increased sodium permeability (spontaneously hypertensive rat). Thus, a sodium channel blocker and a competitor to ouabain binding can detect and determine the functional significance of sodium transport defects in the blood vessels of intact hypertensive animals. Studies in red and white blood cells suggest that similar defects may exist in the blood vessels of hypertensive humans. Thus, this approach, probing for vascular transport defects in the intact animal, may ultimately also be useful in the clinical setting.
...
PMID:Pharmacologic agents for the in vivo detection of vascular sodium transport defects in hypertension. 244 62
Abnormalities in erythrocyte Li-Na countertransport have been reported in hypertensive subjects, and the available evidence favors familial aggregation and striking heritability of this marker. It is uncertain, however, whether the abnormalities are associated with hypertension per se or whether they may be concentrated in a particular subset of hypertensive subjects. In the present study, maximal rates of Li-Na countertransport were measured in red blood cells of 82 white subjects, including 37 normotensive subjects and 45 normal- or high-
renin
hypertensive subjects previously classified as non-modulators (n = 21) or modulators (n = 24). Mean countertransport activity was significantly higher in non-modulators compared with normally modulating hypertensive or normotensive subjects (0.475 +/- 0.044 vs. 0.309 +/- 0.028 or 0.249 +/- 0.012 mmol/l cell x hr, respectively, p less than 0.001). Modulators did not differ significantly from normotensive subjects with regard to mean countertransport activity. Red blood cell
sodium pump
and Na-K-Cl cotransport were not significantly different in modulating and non-modulating hypertensive subjects. These relations remained unchanged after adjusting for age, body weight, and plasma cholesterol levels by analysis of covariance. A countertransport value exceeding 0.50 mmol/l cell x hr occurred in 40% of the non-modulators but in only one of the other subjects. In contrast , while one half of the modulators and normotensive subjects had a countertransport value less than 0.235 mmol/l cell x hr, none of the non-modulators did. Thus, elevated countertransport appears to aggregate in the non-modulating subset of essential hypertensive subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Red blood cell lithium-sodium countertransport in non-modulating essential hypertension. 254 20
This review summarizes our bioassay methods for determining the level of humoral
sodium pump
inhibiting factor after acute volume expansion in experimental animals and humans, and in low
renin
experimental and human essential hypertension. In brief, ouabain-sensitive 86Rb uptake and membrane potential in blood vessels from normal animals are measured after incubation in plasma supernate from experimental subjects and animals and their respective controls. The data show that humoral
sodium pump
inhibitor is elevated after acute volume expansion in normal animals (dogs and rats) and in normal humans. The level of inhibitor is also elevated in patients with low
renin
essential hypertension and in experimental animals with low
renin
, volume-dependent types of hypertension, namely, one-kidney, one wrapped hypertension in dogs, and one-kidney, one clip and reduced renal mass-saline hypertension in rats. Humoral
sodium pump
inhibiting factor inhibits the Na+-K+ pump in the cardiovascular system. Such inhibition by other means (hypokalemia, cardiac glycosides) activates the system. Therefore, we also discuss the possible role of humoral
sodium pump
inhibitor in low
renin
volume-dependent hypertension.
...
PMID:Humoral sodium transport inhibitor in acute volume expansion and low renin hypertension. 282 71
1
2
3
Next >>